Advance in renal cell carcinoma in 2022 ASCO-GU
10.3760/cma.j.cn112330-20220410-00186
- VernacularTitle:2022 ASCO-GU肾细胞癌精粹解析
- Author:
Hao ZENG
1
;
Zhenhua LIU
Author Information
1. 四川大学华西医院泌尿外科，成都 610041
- Keywords:
Carcinoma, Renal cell;
Immunotherapy;
Targeted therapy;
Adjuvant therapy;
Neoadjuvant therapy
- From:
Chinese Journal of Urology
2022;43(4):249-252
- CountryChina
- Language:Chinese
-
Abstract:
ASCO-GU is one of the landmark meetings of urogenital cancer. Within 2022 meeting, the extended follow up result of adjuvant pembrolizumab after nephrectomy in renal cell carcinoma as well as the efficacy and safety of neoadjuvant Axitinib and avelumab for local advanced renal cell carcinoma have been released. There were also explorations in local therapy for oligometastasis, novel combination system therapy and regiments alterations. The further research protocol of immunostimulatory IL-2 cytokine prodrug and PARP inhibitor for metastatic RCC were also disclosed.
